<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(13)</volume><submitter>Thomas D</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>To investigate the correlation between rs1568885, rs1813443 and rs4411591 polymorphisms and response to infliximab in a cohort of Greek patients with Crohn's disease (CD).&lt;h4>Methods&lt;/h4>One hundred and twenty-six patients diagnosed with CD based on standard clinical, endoscopic, radiological, and pathological criteria were enrolled in this study at the Gastroenterology Unit of the 2(nd) Department of Surgery and at the Colorectal Unit of the 1st Department of Propaedeutic Surgery. Infliximab at a dose of 5 mg/kg was administered intravenously at weeks 0, 2, 6 and then every 8 wk. Clinical and serological responses were assessed using the Harvey-Bradshaw Index and serum C-reactive protein (CRP) levels, respectively, and the endoscopic response was evaluated by ileocolonoscopy p</pubmed_abstract><journal>World journal of gastroenterology</journal><pagination>3609-14</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3974528</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease.</pubmed_title><pmcid>PMC3974528</pmcid><pubmed_authors>Rigoglou S</pubmed_authors><pubmed_authors>Gazouli M</pubmed_authors><pubmed_authors>Karantanos T</pubmed_authors><pubmed_authors>Zografos G</pubmed_authors><pubmed_authors>Theodoropoulos GE</pubmed_authors><pubmed_authors>Thomas D</pubmed_authors><pubmed_authors>Bramis K</pubmed_authors><pubmed_authors>Karamanolis G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease.</name><description>&lt;h4>Aim&lt;/h4>To investigate the correlation between rs1568885, rs1813443 and rs4411591 polymorphisms and response to infliximab in a cohort of Greek patients with Crohn's disease (CD).&lt;h4>Methods&lt;/h4>One hundred and twenty-six patients diagnosed with CD based on standard clinical, endoscopic, radiological, and pathological criteria were enrolled in this study at the Gastroenterology Unit of the 2(nd) Department of Surgery and at the Colorectal Unit of the 1st Department of Propaedeutic Surgery. Infliximab at a dose of 5 mg/kg was administered intravenously at weeks 0, 2, 6 and then every 8 wk. Clinical and serological responses were assessed using the Harvey-Bradshaw Index and serum C-reactive protein (CRP) levels, respectively, and the endoscopic response was evaluated by ileocolonoscopy p</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Apr</publication><modification>2025-05-29T20:49:39.255Z</modification><creation>2019-06-06T12:34:54Z</creation></dates><accession>S-EPMC3974528</accession><cross_references><pubmed>24707144</pubmed><doi>10.3748/wjg.v20.i13.3609</doi></cross_references></HashMap>